KR20190065315A - Trh 아날로그 및 아룬드산을 조합하여 이루어지는 조성물, 그리고 아룬드산의 약학적으로 허용되는 염 - Google Patents

Trh 아날로그 및 아룬드산을 조합하여 이루어지는 조성물, 그리고 아룬드산의 약학적으로 허용되는 염 Download PDF

Info

Publication number
KR20190065315A
KR20190065315A KR1020197011464A KR20197011464A KR20190065315A KR 20190065315 A KR20190065315 A KR 20190065315A KR 1020197011464 A KR1020197011464 A KR 1020197011464A KR 20197011464 A KR20197011464 A KR 20197011464A KR 20190065315 A KR20190065315 A KR 20190065315A
Authority
KR
South Korea
Prior art keywords
component
composition
acid
pharmaceutically acceptable
synthesis example
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197011464A
Other languages
English (en)
Korean (ko)
Inventor
미치오 야마무라
나리토 다테이시
Original Assignee
브리벤션 파마슈티컬 (상하이) 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리벤션 파마슈티컬 (상하이) 인크. filed Critical 브리벤션 파마슈티컬 (상하이) 인크.
Publication of KR20190065315A publication Critical patent/KR20190065315A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020197011464A 2016-10-03 2017-09-27 Trh 아날로그 및 아룬드산을 조합하여 이루어지는 조성물, 그리고 아룬드산의 약학적으로 허용되는 염 Ceased KR20190065315A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016195505 2016-10-03
JPJP-P-2016-195505 2016-10-03
JPJP-P-2017-184731 2017-09-26
JP2017184731 2017-09-26
PCT/JP2017/034926 WO2018066427A1 (ja) 2016-10-03 2017-09-27 Ｔｒｈアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Publications (1)

Publication Number Publication Date
KR20190065315A true KR20190065315A (ko) 2019-06-11

Family

ID=61832036

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011464A Ceased KR20190065315A (ko) 2016-10-03 2017-09-27 Trh 아날로그 및 아룬드산을 조합하여 이루어지는 조성물, 그리고 아룬드산의 약학적으로 허용되는 염

Country Status (16)

Country Link
US (1) US10828303B2 (https=)
EP (1) EP3520795B1 (https=)
JP (2) JP6596697B2 (https=)
KR (1) KR20190065315A (https=)
CN (2) CN113559102B (https=)
AU (1) AU2017340594B2 (https=)
BR (1) BR112019006429A2 (https=)
CA (1) CA3039027A1 (https=)
CO (1) CO2019003255A2 (https=)
IL (1) IL265688A (https=)
MX (1) MX2019003837A (https=)
PH (1) PH12019500636A1 (https=)
SG (1) SG11201902599SA (https=)
TW (1) TW201818939A (https=)
WO (1) WO2018066427A1 (https=)
ZA (1) ZA201902341B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907591D0 (en) * 2019-05-29 2019-07-10 Eolas Res Limited Composition and use
IT202000015895A1 (it) 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0782166A (ja) 1993-09-14 1995-03-28 Tanabe Seiyaku Co Ltd 抗ショック剤
JPH07316092A (ja) 1993-06-01 1995-12-05 Ono Pharmaceut Co Ltd ペンタン酸誘導体、その製造方法およびそれらを含有する薬剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6223429A (ja) * 1985-07-24 1987-01-31 Ishikawajima Harima Heavy Ind Co Ltd 水素同位体の回収・貯蔵・供給装置
JPS62234029A (ja) 1985-12-27 1987-10-14 Tanabe Seiyaku Co Ltd 中枢神経賦活剤
US9016221B2 (en) * 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
JP4730303B2 (ja) 2004-04-28 2011-07-20 小野薬品工業株式会社 （２ｒ）−２−プロピルオクタン酸とアミンとからなる結晶
JP2006143708A (ja) 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
TWI680117B (zh) * 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
EP2443120B1 (en) * 2009-06-16 2016-11-02 RSPR Pharma AB Crystalline form of pemirolast
CN102786414B (zh) * 2012-08-15 2014-07-16 四川大学 一类用于治疗和/或预防神经退行性相关疾病的化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07316092A (ja) 1993-06-01 1995-12-05 Ono Pharmaceut Co Ltd ペンタン酸誘導体、その製造方法およびそれらを含有する薬剤
JPH0782166A (ja) 1993-09-14 1995-03-28 Tanabe Seiyaku Co Ltd 抗ショック剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yamamura M, et al., 1991, Japan. J. Pharmacol. Vol. 55. p241-253

Also Published As

Publication number Publication date
PH12019500636A1 (en) 2019-10-28
AU2017340594B2 (en) 2020-09-10
CN110267661B (zh) 2021-08-03
CN113559102A (zh) 2021-10-29
JP6596697B2 (ja) 2019-10-30
BR112019006429A2 (pt) 2019-06-25
JPWO2018066427A1 (ja) 2019-07-25
EP3520795A1 (en) 2019-08-07
TW201818939A (zh) 2018-06-01
CO2019003255A2 (es) 2019-04-12
US10828303B2 (en) 2020-11-10
WO2018066427A1 (ja) 2018-04-12
EP3520795A4 (en) 2020-05-13
CA3039027A1 (en) 2018-04-12
AU2017340594A1 (en) 2019-04-18
IL265688A (en) 2019-05-30
SG11201902599SA (en) 2019-05-30
CN110267661A (zh) 2019-09-20
JP2019203007A (ja) 2019-11-28
NZ752311A (en) 2020-12-18
ZA201902341B (en) 2020-08-26
CN113559102B (zh) 2023-01-03
US20190240221A1 (en) 2019-08-08
MX2019003837A (es) 2019-06-24
EP3520795B1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
US20250326752A1 (en) Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
KR20250012083A (ko) 피페리딘일-메틸-푸린 아민 d-타르타르산 염, 결정질 형태 및 의학적 질환 및 병태 치료에서의 이들의 용도
CN102234287B (zh) 硝基咪唑类化合物、其制备方法和用途
IL269424B2 (en) New therapeutic use of h3-ligands
US20250171445A1 (en) Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
KR20190065315A (ko) Trh 아날로그 및 아룬드산을 조합하여 이루어지는 조성물, 그리고 아룬드산의 약학적으로 허용되는 염
TWI462915B (zh) 一種組織胺ｈ３受體拮抗劑的新穎富馬酸鹽
CN113166071A (zh) 尼拉帕利盐
CA3142963C (en) Use of aminothiol compounds as cerebral nerve or heart protective agent
WO2021047528A1 (zh) 一个烟醇醚衍生物的马来酸盐及其晶型和应用
WO2012001438A1 (en) Use of kynurenic acid amide derivatives for the treatment of huntington's disease
NZ752311B2 (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
HK40005518A (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
CN113166064B (zh) 胆碱酯酶抑制剂多晶型及其应用
CN104093703B (zh) Mglu 2/3激动剂
CN109988199B (zh) 红景天苷衍生物及其用途
HK40025304A (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EA050218B1 (ru) Производные 6-метилурацила, обладающие антихолинэстеразной активностью, и их применение
CN120569387A (zh) Par2的小分子调节剂及其用途
HK40093043A (zh) GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
CN110358074A (zh) 淫羊藿苷元衍生物及其制备方法和用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190422

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200917

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220916

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220916

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I